Used by AstraZeneca, Janssen Pharmaceuticals, Oxford Nanopore, and over 150 leading pharmaceutical and biotechnology companies, and a driving force behind the fight against Covid-19, Barcelona-based Seqera Labs has raised €22 million in a Series A funding round.
The fresh capital is aimed at helping the data orchestration and workflow software for life sciences startup further flesh out the headcount as it expands its product lineup to cover the entire data analysis lifecycle. Since March of 2019, Seqera Labs has raised €27.6 million, which includes several grants from the Chan Zuckerberg Initiative.
Addition fund led the round with existing investors Talis Capital, Speedinvest, BoxOne Ventures, and Amino Collective participating.
Founded in 2018 as a spin-off from the Centre for Genomic Regulation (CRG), Seqera Labs builds upon the teams’ earlier creation, Nextflow, a popular open-source workflow, and data orchestration software used by cloud providers, sequencing companies, and genomics platforms.
According to the company, year-over-year revenue increase numbers are in the range of 400%, and within the past 12 months, the staff roster has tripled in size. As you might imagine in conjunction with AstraZeneca (and others, of course), Seqera Labs’s services played a crucial role in the fight against Covid-19, namely in the variant detection sector with its technology used to discover and track Alpha, Delta, and Omicron variants.
“The biotechnology industry is undergoing a transformational shift and organizations must rapidly expand their capacity to process complex data at scale,” commented Addition’s (also former Tiger Global Partner) Jason Schneider. “Seqera Labs’ products make this easier than ever before and allow research teams to remain focused on their critical work. We’re proud to support Evan and his talented team as they continue on their impressive growth trajectory and lead breakthrough innovations in healthcare and life sciences.”
Would you like to write the first comment?Login to post comments